You are here

Home » Content

Hiperhomosisteinemi ve Düşük Kobalamin Düzeyi Olan Metilentetrahidrofolat Redüktaz C677T Heterozigot Mutasyonlu bir Hastada Renal Arter Tromboembolisi

Renal Artery Thromboembolism in a Patient with Hyperhomocysteinemia, Low Cobalamin Level, and a Methylenetetrahydrofolate Reductase C677T Heterozygous Mutation

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2009

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
We present the case of a 56-year-old man with a renal artery thrombosis. The patient’s medical history was significant for a myocardial infarction 1 year earlier. There was no history of trauma, smoking, hypertension, or diabetes mellitus. In addition to the unilateral renal arterial thrombosis, our patient had hyperhomocysteinemia, a low cobalamin level, and a heterozygous C677T mutation of the methylene tetrahydrofolate reductase (MTHFR) gene. The homocysteine level decreased with cobalamin treatment. Other causes of thrombophilia were ruled out. In the current patient, we suggest that the cause of the previous myocardial infarction and recent renal artery thromboembolism might have been associated with the effects of hyperhomocysteinemia, a low cobalamin level, and presence of a heterozygous C677T mutation of the MTHFR gene.
Bookmark/Search this post with
Abstract (Original Language): 
Bu yazıda 56 yaşındaki bir erkek hastada gelişen renal arter tromboembolisi vakasını sunduk. Hastanın özgeçmişinde bir yıl önce geçirilmiş miyokard enfarktüsü öyküsü vardı. Hastada sigara, hipertansiyon, diabetes mellitus ve travma öyküsü olmamasına rağmen tek taraflı renal arter tromboembolisi gelişmişti. Embolinin yanısıra hastada hiperhomosisteinemi, düşük kobalamin düzeyi ve metilentetrahidrofolat redüktaz C677T heterozigot mutasyonu (MTHFR) saptandı. Kobalamin tedavisini takiben homosistein düzeyleri düştü. Diğer trombofili sebepleri ise ekarte edildi. Bu hastada önceki miyokard enfarktüsünün ve yeni renal arter tromboembolisinin hiperhomosisteinemi, düşük kobalamin düzeyi ve MTHFR mutasyonu ile ilişkili olabileceği düşündük.
FULL TEXT (PDF): 
PDF icon arastrmx_172977_18_pp_144-146.pdf
  • 3
144-146
  • Turkish

REFERENCES

References: 

1. Scoble JE: Renal vascular thrombosis and occlusion, in
Johnson RJ, Feehally J (eds): Comprehensive Clinical
Nephrology (ed 2). Philadelphia: Elsevier, 2003; 825-834
2. Levin M, Nakhoul F, Keidar Z, Green J: Acute oliguric
renal failure associated with unilateral renal embolism: A
successful treatment with iloprost. Am J Nephrol 1998; 18:
444-447
3. den Heijer M, Koster T, Blom HJ, Bos GM, Briet
E, Reitsma PH, Vandenbroucke JP, Rosendaal FR:
Hyperhomocysteinemia as a risk factor for deep-vein
thrombosis. N Eng J Med 1996; 334: 759-762
4. Rees MM, Rodgers GM: Homocysteinemia: association of
a metabolic disorder with vascular disease and thrombosis.
Throm Res 1993; 71: 337-359
5. Manfredini R, La Cecilia O, Ughi G, Kuwornu H, Bressan
S, Regoli F, Orzincolo C, Daniele C, Gallerani M: Renal
infarction: an uncommon mimic presenting with flank pain.
Am J Emerg Med 2000; 18: 325-327
6. Soussou ID, Starr DS, Lawrie GM, Morris GC: Renal artery
aneurysm. Long-term relief of renovascular hypertension
by in situ operative correction. Arch Surg 1979; 114:1410-
1415
7. Lessman RK, Johnson SF, Coburn JW, Kaufman JJ: Renal
artery embolism, clinical features and long-term follow-up
of 17 cases. Ann Intern Med 1978; 89: 477-482
8. Ischemic renal disease, in Alex M, Davison J, Stewart C,
Jean-Pierre G, David NSK, Eberhard R, et al (eds): Oxford
Textbook of Clinical Nephrology Vol. 2 (ed 2). New York,
NY: Oxford, 1998; 1679-1688
9. Domanovits H, Paulis M, Nikfardjam M, Meron G,
Kurkciyan I, Bankier AA, et al: Acute renal infarction:
clinical characteristics of 17 patients. Medicine 1999; 78:
386-394
10. Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia.
An emerging and important risk factor for thromboembolic
and cardiovascular disease. Am J Clin Pathol 1996; 105:
709-722
11. Guttormsen AB, Ueland PM, Nesthus I, Nygard O,
Schneede J, Vollset SE, et al: Determinants and vitamin
responsiveness of intermediate hyperhomocysteinemia.
The Hordaland Homocysteine Study. J Clin Invest 1996;
98: 2174-2183
12. Austin RC, Lentz SR, Werstuck GH: Role of
hyperhomocysteinemia in endothelial dysfunction and
otherothrombotic disease. Cell Death Differ 2004; 11: 56-
64
13. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A
quantitative assessment of plasma homocysteine as a risk
factor for vascular disease: probable benefits of increasing
folic acid intakes. JAMA 1995; 274: 1049-1057
14. Kim RJ, Becker RC: Association between factor V Leiden,
prothrombin G20210A, and methylenetetrahydrofolate
reductase C677T mutations and events of the arterial
circulatory system: A meta-analysis of published studies.
Am Heart J 2003; 146: 948-957

Thank you for copying data from http://www.arastirmax.com